Zonisade (Zonisamide) Patent Expiration, LOE Window & CMS Spending

Zonisade (Zonisamide) by Azurity: FDA Orange Book LOE 2038-08-18, 7 AB generics, $26.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN214273 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-08-18
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$26.6M
2024 Medicare Part D Spend$4.4M
2024 Medicaid Spend$22.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 23.5% 2-yr change)